New mechanistic research finds that mutant p53 spatially reprograms AP-1 transcriptional complexes at the FOSL1 locus, flipping enhancer output into promoter-driven activation that promotes epithelial-mesenchymal transition and cancer cell migration. The work, published in Cell Death Discovery, maps how wild-type p53 suppresses EMT by forming repressive complexes, while mutant p53 redirects c-JUN and FRA1 to a different regulatory element configuration. The study positions the FOSL1 enhancer-promoter axis as a “rheostat” for EMT control, and it suggests a therapeutic strategy focused on selectively disrupting oncogenic AP-1 complexes associated with mutant p53-driven transcription. That reframes mutant p53 biology from a general loss-of-function concept toward actionable gain-of-function regulatory targeting. For drug discovery teams, the translational signal is in identifying a locus-specific transcriptional switching mechanism that can potentially be attacked upstream of phenotype. It may also help define biomarkers—such as AP-1 complex configuration or target locus activity—for patient selection. While still preclinical mechanistic work, the findings provide concrete molecular nodes and an experimentally grounded pathway for future therapeutic development.
Get the Daily Brief